[1]
|
Tanaka, Y., Morita, C.T., Nieves, E., Brenner, M.B. and Bloom, B.R. (1995) Natural and Synthetic Non-Peptide Antigens Recognized by Human γδ T Cells. Letter to Nature, 375, 155-158. https://doi.org/10.1038/375155a0
|
[2]
|
Davey, M.S., Willcox, C.R., Hunter, S., et al. (2018) The Human Vdelta2(+) T-Cell Compartment Comprises Distinct Innate-Like Vgamma9(+) and Adaptive Vgamma9(-) Subsets. Nature Communications, 9, 1760.
https://doi.org/10.1038/s41467-018-04076-0
|
[3]
|
Christopoulos, P., Bukatz, D., Kock, S., et al. (2016) Improved Analysis of TCRgd Variable Region Expression in Humans. The Journal of Immunological Methods, 434, 66-72. https://doi.org/10.1016/j.jim.2016.04.009
|
[4]
|
Fisher, J.P., Yan, M., Heuijerjans, J., et al. (2014) Neuroblastoma Killing Properties of Vd2 and Vd2-Negative CDT Cells Following Expansion by Artificial Antigen-Presenting Cells. Clinical Cancer Research, 20, 5720-5732.
https://doi.org/10.1158/1078-0432.CCR-13-3464
|
[5]
|
Silva-Santos, B., Serre, K. and Norell, H. (2015) γδ T Cells in Cancer. Nature Reviews Immunology, 15, 683-691.
https://doi.org/10.1038/nri3904
|
[6]
|
McCarthy, N.E., Bashir, Z., Vossenkamper, A., et al. (2013) Proinflammatory Vdelta2+T Cells Populate the Human Intestinal Mucosa and Enhance IFN Gamma Production by Colonic Alphabeta T Cells. Journal of Immunology, 191, 2752-2763. https://doi.org/10.4049/jimmunol.1202959
|
[7]
|
Wu, Y.L., Ding, Y.P., Tanaka, Y., Shen, L.W., Wei, C.H., Minato, N. and Zhang, W. (2014) Gammadelta T Cells and Their Potential for Immunotherapy. International Journal of Biological Sciences, 10, 119-135.
https://doi.org/10.7150/ijbs.7823
|
[8]
|
Coffelt, S.B., Kersten, K., Doornebal, C.W., et al. (2015) IL-17-Producing Gammadelta T Cells and Neutrophils Conspire to Promote Breast Cancer Metastasis. Nature, 522, 345-348. https://doi.org/10.1038/nature14282
|
[9]
|
Castro, F., Cardoso, A.P., Goncalves, R.M., et al. (2018) Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Frontiers in Immunology, 9, 847. https://doi.org/10.3389/fimmu.2018.00847
|
[10]
|
Medina, B.D., Liu, M., Vitiello, G.A., et al. (2019) Oncogenic Kinase Inhibition Limits Batf3-Dependent Dendritic Cell Development and Antitumor Immunity. Journal of Experimental Medicine, 216, 1359-1376.
https://doi.org/10.1084/jem.20180660
|
[11]
|
Tyler, C.J., Doherty, D.G., Moser, B. and Eberl, M. (2015) Human Vγ9/Vδ2 T Cells: Innate Adaptors of the Immune System. Cellular Immunology, 296, 10-21. https://doi.org/10.1016/j.cellimm.2015.01.008
|
[12]
|
Cabillic, F., Toutirais, O., Lavoué, V., de La Pintière, C.T., Daniel, P., Rioux-Leclerc, N., Turlin, B., Mönkkönen, H., Mönkkönen, J., Boudjema, K., Catros, V. and Bouet-Toussaint, F. (2010) Aminobisphosphonate-Pretreated Dendritic Cells Trigger Successful Vγ9Vδ2 T Cell Amplification for Immunotherapy in Advanced Cancer Patients. Cancer Immunology, Immunotherapy, 59, 1611-1619. https://doi.org/10.1007/s00262-010-0887-0
|
[13]
|
Bennouna, J., Bompas, E., Neidhardt, E.M., Rolland, F., Philip, I., Galéa, C., Salot, S., Saiagh, S., Audrain, M., Rimbert, M., Lafaye-de Micheaux, S., Tiollier, J. and Négrier, S. (2008) Phase-I Study of Innacell γδ™, an Autologous Cell-Therapy Product Highly Enriched in γ9δ2 T Lymphocytes, in Combination with IL-2, in Patients with Metastatic Renal Cell Carcinoma. Cancer Immunology, Immunotherapy, 57, 1599-1609.
https://doi.org/10.1007/s00262-008-0491-8
|
[14]
|
Liu, Z.Y., Guo, B. and Lopez, R.D. (2009) Expression of Intercellular Adhesion Molecule (ICAM)-1 or ICAM-2 Is Critical in Determining Sensitivity of Pancreatic Cancer Cells to Cytolysis by Human Gamma Delta-T Cells: Implications in the Design of Gamma Delta-T-Cell-Based Immunotherapies for Pancreatic Cancer. Journal of Gastroenterology and Hepatology, 24, 900-911. https://doi.org/10.1111/j.1440-1746.2008.05668.x
|
[15]
|
Devaud, C., Bilhere, E., Loizon, S., et al. (2009) Antitumor Activity of Gammadelta T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model. Cancer Research, 69, 3971-3978.
https://doi.org/10.1158/0008-5472.CAN-08-3037
|
[16]
|
Benzaid, I., Monkkonen, H. and Clezardin, P. (2011) Effects of Zoledronic Acid and Denosumab on Human V Gamma 9V Delta 2 T-Cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells. European Journal of Cancer, 47, S117. https://doi.org/10.1016/S0959-8049(11)70717-1
|
[17]
|
Nakajima, J., Murakawa, T., Fukami, T., et al. (2010) A Phase I Study of Adoptive Immunotherapy for Recurrent Non-Small-Cell Lung Cancer Patients with Autologous Gammadelta T Cells. European Journal of Cardio-Thoracic Surgery, 37, 1191-1197. https://doi.org/10.1016/j.ejcts.2009.11.051
|
[18]
|
Bialasiewicz, A.A., Ma, J.X. and Richard, G. (1999) αβ- and γδ TCR+ Lymphocyte Infiltration in Necrotising Choroidal Melanomas. British Journal of Ophthalmology, 83, 1069-1073. https://doi.org/10.1136/bjo.83.9.1069
|
[19]
|
Kuyama, H., Hagi, T., Mattarollo, S., et al. (2008) Vgamma9Vdelta2 T Cell Cytotoxicity against Tumor Cells Is Enhanced by Monoclonal Antibody Drugs Rituximab and Trastuzumab. International Journal of Cancer, 122, 2526-2534.
https://doi.org/10.1002/ijc.23365
|
[20]
|
Fabre, J., Giustiniani, J., Garbar, C., et al. (2016) Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. International Journal of Molecular Sciences, 17, 1433.
https://doi.org/10.3390/ijms17091433
|
[21]
|
Rei, M., Goncalves-Sousa, N., Lanca, T., et al. (2014) Murine CD27-Vc6+ γδ T Cells Producing IL-17A Promote Ovarian Cancer Growth via Mobilization of Protumor Small Peritoneal Macrophages. Proceedings of the National Academy of Sciences of the United States of America, 111, E3562-E3570. https://doi.org/10.1073/pnas.1403424111
|
[22]
|
Daley, D., Zambirinis, C.P., Seifert, L., et al. (2016) γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation. Cell, 166, 1485-1499e1415. https://doi.org/10.1016/j.cell.2016.07.046
|
[23]
|
Jin, C., Lagoudas, G.K., Zhao, C., et al. (2019) Commensalmicrobiota Promote Lung Cancer Development via γδ T Cells. Cell, 176, 998-1013e1016. https://doi.org/10.1016/j.cell.2018.12.040
|
[24]
|
Ma, C.L., Zhang, Q.Y., Ye, J., et al. (2012) Tumor-Infiltrating Gamma Delta T Lymphocytes Predict Clinical Outcome in Human Breast Cancer. Journal of Immunology, 12, 1451-1456.
|
[25]
|
Lafont, V., Sanchez, F., Laprevotte, E., et al. (2014) Plasticity of Gammadelta T Cells: Impact on the Antitumor Response. Frontiers in Immunology, 5, 622. https://doi.org/10.3389/fimmu.2014.00622
|
[26]
|
Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., et al. (2010) Tumor-Infiltrating IL-17-Producing γδ T Cells Support the Progression of Tumor by Promoting Angiogenesis. European Journal of Immunology, 40, 1927-1937. https://doi.org/10.1002/eji.200940157
|
[27]
|
Wu, P., Wu, D., Ni, C., et al. (2014) γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer. Immunity, 40, 785-800. https://doi.org/10.1016/j.immuni.2014.03.013
|
[28]
|
Coffelt, S.B., Kersten, K., Doornebal, C.W., et al. (2015) IL-17 Producing γδ T Cells and Neutrophils Conspire to Promote Breast Cancer Metastasis. Nature, 522, 345-348. https://doi.org/10.1038/nature14282
|
[29]
|
Shah, N.N. and Fry, T.J. (2019) Mechanisms of Resistance to CAR T Cell Therapy. Nature Reviews Clinical Oncology, 16, 372-385. https://doi.org/10.1038/s41571-019-0184-6
|
[30]
|
Kabelitz, D., Hinz, T., Dobmeyer, T., Mentzel, U., Marx, S., Böhme, A., Arden, B., Rossol, R. and Hoelzer, D. (1997) Clonal Expansion of Vgamma3/Vdelta3-Expressing Gammadelta T Cells in an HIV-1/2-Negative Patient with CD4 T-Cell Deficiency. British Journal of Haematology, 96, 266-271. https://doi.org/10.1046/j.1365-2141.1997.d01-2027.x
|
[31]
|
Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. and Tanabe, K. (2011) Phase I/II Study of Adoptive Transfer of γδ T Cells in Combination with Zoledronic Acid and IL-2 to Patients with Advanced Renal Cell Carcinoma. Cancer Immunology, Immunotherapy, 60, 1075-1084. https://doi.org/10.1007/s00262-011-1021-7
|
[32]
|
Johnson, J.R., Williams, G. and Pazdur, R. (2003) End Points and United States Food and Drug Administration Approval of Oncology Drugs. Journal of Clinical Oncology, 21, 1404-1411. https://doi.org/10.1200/JCO.2003.08.072
|
[33]
|
Body, J.J. (2006) Bisphosphonates for Malignancy-Related Bone Disease: Current Status, Future Developments. Supportive Care in Cancer, 14, 408-418. https://doi.org/10.1007/s00520-005-0913-5
|
[34]
|
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. and Thun, M.J. (2005) Cancer Statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30. https://doi.org/10.3322/canjclin.55.1.10
|
[35]
|
Liu, Z., Guo, B.L., Gehrs, B.C., Nan, L. and Lopez, R.D. (2005) Ex Vivo Expanded Human Vγ9Vδ2 γδ +T Cells Mediate Innate Antitumor Activity against Human Prostate Cancer Cells in Vitro. The Journal of Urology, 173, 1552-1556.
https://doi.org/10.1097/01.ju.0000154355.45816.0b
|
[36]
|
Viey, E., Fromont, G., Escudier, B., Morel, Y., Da Rocha, S., Chouaib, S., et al. (2005) Phosphostim Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma. Journal of Immunology, 174, 1338-1347.
https://doi.org/10.4049/jimmunol.174.3.1338
|
[37]
|
Kabelitz, D., Wesch, D., Pitters, E. and Zoller, M. (2004) Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδT Cells in Vitro and in SCID Mice in Vivo. Journal of Immunology, 173, 6767-6776.
https://doi.org/10.4049/jimmunol.173.11.6767
|
[38]
|
D’Asaro, M., La Mendola, C., Di Liberto, D., Orlando, V., Todaro, M., Spina, M., et al. (2010) Vγ9Vδ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. Journal of Immunology, 184, 3260-3268. https://doi.org/10.4049/jimmunol.0903454
|
[39]
|
Lang, J.M., Kaikobad, M.R., Wallace, M., Staab, M.J., Horvath, D.L., Wilding, G., Liu, G., Eickhoff, J.C., McNeel, D.G. and Malkovsky (2011) Pilot Trial of Interleukin-2 and Zoledronic Acid to Augment γδ T Cells as Treatment for Patients with Refractory Renal Cell Carcinoma. Cancer Immunology, Immunotherapy, 60, 1447-1460.
https://doi.org/10.1007/s00262-011-1049-8
|
[40]
|
Van Acker, H.H., Anguille, S., Van Tendeloo, V.F. and Lion, E. (2015) Empowering Gamma Delta T Cells with Antitumor Immunity by Dendritic Cell-Based Immunotherapy. Oncolimmunology, 4, e1021538.
https://doi.org/10.1080/2162402X.2015.1021538
|
[41]
|
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C.T., Spies, T., et al. (2001) MICA Engagement by Human Vγ9Vδ2 T Cells Enhances Their Antigen Dependent Effector Function. Immunity, 15, 83-93.
https://doi.org/10.1016/S1074-7613(01)00168-6
|
[42]
|
Rincon-Orozco, B., Kunzmann, V., Wrobel, P., Kabelitz, D., Steinle, A. and Herrmann, T. (2005) Activation of Vγ9Vδ2 T Cells by NKG2D. Journal of Immunology, 175, 2144-2151. https://doi.org/10.4049/jimmunol.175.4.2144
|
[43]
|
Dieli, F., Troye-Blomberg, M., Ivanyi, J., Fournie, M., Bonneville, M.A., Peyrat, G., et al. (2001) Granulysin Dependent Killing of Intracellular and Extracellular Mycobacterium tuberculosis by Vγ9Vδ2 T Lymphocytes. The Journal of Infectious Diseases, 184, 1082-1085. https://doi.org/10.1086/323600
|
[44]
|
Vermijlen, D., Ellis, P., Langford, C., Klein, A., Engel, R., Willimann, K., et al. (2007) Distinct Cytokine Driven Responses of Activated Blood γδ T Cells: Insights into Unconventional T Cell Pleiotropy. Journal of Immunology, 178, 4304-4314. https://doi.org/10.4049/jimmunol.178.7.4304
|
[45]
|
Dalton, J.E., Howell, G., Pearson, J., Scott, P. and Carding, S.R. (2004) Fas-Fas Ligand Interactions Are Essential for the Binding to and Killing of Activated Macrophages by γδ. Journal of Immunology, 173, 3660-3667.
https://doi.org/10.4049/jimmunol.173.6.3660
|
[46]
|
Ismaili, J., Olislagers, V., Poupot, R., Fournie, J.J. and Goldman, M. (2002) Human γδ T Cells Induce Dendritic Cell Maturation. Clinical Immunology, 103, 296-302. https://doi.org/10.1006/clim.2002.5218
|
[47]
|
Tosolini, M., Pont, F., Poupot, M., et al. (2017) Assessment of Tumor-Infiltrating TCR Vγ9Vδ2 γδ Lymphocyte Abundance by Deconvolution of Human Cancers Microarrays. Oncoimmunology, 6, e1284723.
https://doi.org/10.1080/2162402X.2017.1284723
|
[48]
|
Buccheri, S., Guggino, G., Caccamo, N., Li Donni, P. and Dieli, F. (2014) Efficacy and Safety of γδ T Cell-Based Tumor Immunotherapy: A Meta-Analysis. Journal of Biological Regulators and Homeostatic Agents, 28, 81-90.
|